Anti-CCL2 (Carlumab)-VcMMAE
Anti-CCL2 (Carlumab)-VcMMAE is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated with valine-citrulline (vc) and the tubulin inhibitor MMAE (HY-15162). The ADC toxic molecule and linker part are McMMAE (HY-15575). Anti-CCL2 (Carlumab)-VcMMAE induces apoptosis and can be used in cancer research.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Chemical Information
-
SMILES
[Anti-CCL2 (Carlumab)-VcMMAE]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Fetterly GJ, et al. Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. J Clin Pharmacol. 2013 Oct;53(10):1020-7. [Content Brief]
[2]. Okeley NM, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010 Feb 1;16(3):888-97. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)